Salmonella

细菌转染

Resumen de: AU2023361317A1

The present invention relates to a modified live attenuated Gram-negative bacteria, wherein said bacteria has been modified in such a way that RNA molecules can be safely and efficiently delivered to target eukaryotic cells. As such, the present invention relates a to a bacterial delivery system and various uses and methods thereof.

LYTIC PHAGE WITH HIGH SPECIFICITY TOWARDS PATHOGENIC ESCHERICHIA COLI

Resumen de: US2025164483A1

Herein are presented methods for incorporating a novel bacteriophage, CAM-21, that exhibits lytic activity against pathogenic E. coli, into food, food packaging, films, and quantum dot-based biosensors. The bacteriophage contains no genes associated with toxins, virulence factors, antibiotic resistance, lysogeny, or allergens. Methods are provided for encapsulating the bacteriophage with proteins and/or carbohydrate materials to enhance stability. Various films in which the bacteriophage are incorporated, and which similarly exhibit suppression of pathogenic E. coli, are also provided. Additionally, when conjugated with N-doped graphene quantum dots, CAM-21 enables biosensor development for E. coli detection in food products through altered photoluminescence emission spectra, and methods for making and using such biosensors are provided.

SELF-ASSEMBLING PROTEIN NANOPARTICLES ENCAPSULATING IMMUNOSTIMULATORY NUCLEID ACIDS

Resumen de: US2025161423A1

The present invention relates to self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids. Furthermore, the invention relates to the use of such nanoparticles for vaccination.

LACTIPLANTIBACILLUS PLANTARUM GOLDGUT-LP618 HAVING FUNCTION OF RESISTING SALMONELLA INFECTION AND APPLICATION THEREOF

Resumen de: AU2024256082A1

The present invention relates to the technical field of probiotics, in particular to a Lactiplantibacillus plantarum GOLDGUT-LP618 having a function of resisting Salmonella infection and application thereof. The Lactiplantibacillus plantarum GOLDGUT-LP618 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28399. The strain has high resistance to acid and bile salt and can adapt to the digestive tract environment. The strain can inhibit Salmonella infection, relieve diarrhea, inflammation and intestinal damage caused by Salmonella infection, and promote intestinal health. The strain can be used for preparing functional foods, dietary supplements or drugs that can resist Salmonella infection and improve diarrhea and inflammation caused by Salmonella infection, and has good application prospects.

METHOD FOR PREPARING FREEZING SHOCK-TREATED MONOCYTES OR MACROPHAGES LOADED WITH ATTENUATED SALMONELLA AND USE THEREOF

Resumen de: WO2025102801A1

Provided are a method for preparing freezing shock-treated monocytes or macrophages loaded with attenuated Salmonella and the use thereof. The method comprises: loading engineering-modified attenuated Salmonella in monocytes or macrophages, and performed a freezing shock treatment on the monocytes or macrophages loaded with the strain by means of liquid nitrogen. The method for preparing the freezing shock-treated immune cells loaded with the strain is simple and easy to operate. The source problem of the monocytes or macrophages loaded with the engineering-modified attenuated Salmonella is solved, and the method has good application prospects. According to the strategy, by means of avoiding exposure and heterologous stimulation of bacteria, the biological safety of bacteria-based anti-tumor treatment is improved; and the anti-tumor immune response is promoted by means of the high titer of an intratumoral strain, so that a stronger anti-tumor efficacy is obtained.

IMMUNOENHANCING SALMONELLA STRAIN FOR TREATMENT OF CANCER AND USE THEREOF

Resumen de: AU2023382983A1

The present invention relates to a DNA construct including: a gene encoding a flagellin protein; and a gene encoding an immunoenhancer (adjuvant) protein. For effective cancer therapy by selectively killing only cancer cells, an attenuated Salmonella strain according to the present disclosure is designed to produce immunogenic substances in cancer tissue to induce a strong anti-cancer immune response, whereby tumor sizes in metastatic cancers as well as primary cancers can be significantly inhibited. Thus, the strain can be advantageously used in a prophylactic or therapeutic composition for improving survival rates.

DNA CONSTRUCT FOR EXPRESSING SIGNALING SUBSTANCE FOR CANCER TREATMENT, AND CANCER TREATMENT METHOD USING SAME

Resumen de: WO2025100987A1

Cyclic dinucleotides, which are a type of signaling substance for cancer treatment, are secondary messengers of intracellular events initiated by GPCR activation and act as a stimulator of interferon genes (STING), and thus can have a significant effect on tumor suppression. Meanwhile, when cancer occurs in a subject, angiogenesis and cell growth proceed at a very high rate in the body, and thus an oxygen-deficient environment is created due to incomplete angiogenesis in cancer tissues, which may be very suitable for the proliferation of anaerobic bacteria such as Salmonella sp. strains or E. coli. Therefore, the present invention relates to a DNA construct into which is introduced a gene for an enzyme that synthesizes a signaling substance for cancer treatment, e.g., a cyclic dinucleotide, or to a strain transformed with a vector comprising the DNA construct. The DNA construct or the strain transformed with a vector comprising the DNA construct, according to the present invention, targets cancer in a subject and then secretes C-di-AMP or C-di-GMP synthase in the surrounding environment of the cancer, and thus can very effectively prevent or treat cancer and, at the same time, can diagnose cancer in real time.

탄수화물-기반 항-살모넬라 백신의 개발

Resumen de: AU2023312737A1

Provided herein are vaccine composition comprising a

STREPTOCOCCUS SALIVARIUS SUBSP.THERMOPHILUS VB331 AND USE THEREOF

Resumen de: WO2025092264A1

Provided in the present invention are Streptococcus salivarius subsp.thermophilus VB331 and the use thereof. The strain is deposited at the China General Microbiological Culture Collection Center, with the deposit number of CGMCC NO.28407. The Streptococcus salivarius subsp.thermophilus can effectively inhibit the colonization, propagation and growth of various digestive tract pathogenic bacteria, including Escherichia coli, Staphylococcus aureus, Salmonella, Enterococcus faecalis, Listeria monocytogenes and Shigella, and especially has a strong inhibitory effect on Clostridium perfringens. The strain is a natural strain, is very safe, and can provide a new source of probiotics for the development of antibacterial, bacteriostatic and other functional products against multiple harmful bacterial infections.

CAPTURE COMPOSITIONS

Resumen de: US2025147011A1

Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently-linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication. Uses of a Molecular Net may include analyte capture, analyte enrichment, analyte purification, analyte detection, analyte measurement and analyte delivery. Molecular Nets may be used in liquid phase or on solid phases such as nanomaterials, modified metal surfaces, nanospheres, microspheres, microtiter plates, slides, pipettes, cassettes, cartridges, discs, probes, lateral flow devices, microfluidics devices, microfluidics devices, optical fibers and others.

一种减毒鼠伤寒沙门氏菌EN-VNP菌株及其制备方法和应用

Resumen de: CN119932072A

本发明公开了一种减毒鼠伤寒沙门氏菌EN‑VNP菌株及其制备方法和应用，减毒鼠伤寒沙门氏菌EN‑VNP菌株的制备方法，包括如下步骤：在沙门氏菌VNP20009菌株基础上依次敲除或沉默鞭毛蛋白基因fliC、fljB、磷酸乙醇胺转移酶基因eptA、4‑氨基‑4‑脱氧‑L‑阿拉伯糖转移酶基因arnT、磷酸转移酶yeiU以及敲入或过表达磷酸转移酶基因lpxE之后形成的菌株，制得减毒鼠伤寒沙门氏菌EN‑VNP菌株。本发明的具有低毒和T细胞佐剂效果的减毒鼠伤寒沙门氏菌EN‑VNP及其制备的EN‑OMV抗原递送系统，使改善后的菌株不含有鞭毛蛋白且LPS分子结构发生改变，具有低毒和T细胞佐剂效果，且能够正常扩增培养。

IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF

Resumen de: US2025134980A1

The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from Salmonella serovar strains S. typhi; S. paratyphi A; S. typhimurium and S. enteritidis and alternative improved methods of polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation. The present disclosure further relates to methods for inducing an immune response in subjects against Salmonella and non-typhi related diseases and/or for reducing or preventing Salmonella typhi and non-typhi related diseases in subjects using the compositions disclosed herein. The vaccine elicits bactericidal antibodies and is useful for prevention of gastroenteritis, enteric and typhoid fever.

MULTIPLEX PANEL FOR DETECTING VIRAL, BACTERIAL, AND PARASITIC NUCLEIC ACIDS

Resumen de: WO2025090839A1

Described herein are compositions, methods, and kits for detecting diarrhea causing pathogens from patient, food, or environmental samples. One embodiment described herein is primer pairs and probes for multiplex polymerase chain reaction (PCR) based assays for the detection of gastrointestinal pathogens, such as Adenovirus, Astrovirus, Rotavirus, Norovirus, Sapovirus, Campylobacter species, Clostridium difficile, Enteroaggregative E. coli (EAEC), Enteropathogenic E. coli (EPEC), Enterotoxigenic E. coli (ETEC), Shiga-like toxin-producing E. coli (STEC), Shigella/Enteroinvasive E. coli (EIEC), E. coli O157, Listeria monocytogenes, Plesiomonas shigelloides, Salmonella species, Yersinia enterocolitica, Vibrio species, Cryptosporidium species, Cyclospora cayetanensis, Entamoeba histolytica, Giardia intestinalis, or Giardia lamblia. Other embodiments include methods and kits for detecting gastrointestinal pathogens.

BREAST MILK-DERIVED LIMOSILACTOBACILLUS FERMENTUM MSJK0025 CAPABLE OF IMPROVING INTESTINAL FLORA CONDITION AND USE THEREOF

Resumen de: EP4545628A1

The present application relates to a Limosilactobacillus fermentum MSJK0025 from breast milk for adjusting gut microbiota and an application thereof. The Limosilactobacillus fermentum MSJK0025 from breast milk is preserved in China General Microbiological Culture Collection Center, with a preservation number of CGMCC No.26426. The Limosilactobacillus fermentum from breast milk provided in the present application is a new strain separated from the healthy nursing woman, named as "Limosilactobacillus fermentum MSJK0025", having good antibiotics sensitivity, and its property can be stably inherited. It has good resistance to acid, bile salt, and artificial gastric juice and intestinal juice, and fast growth rate and good safety. At the same time, the strain has strong survival capability in the gut, and effectively inhibits pathogenic bacteria in the gut such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium, and Candida albicans, but does not inhibit the probiotic in the gut such as lactobacillus and bifidobacterium, so the strain has broad application prospect in adjusting the balance of gut microbiota.

基于碳水化合物的抗沙门氏菌属疫苗的研发

Resumen de: AU2023312737A1

Provided herein are vaccine composition comprising a

IMMUNOSTIMULATORY COMPOSITION

Resumen de: US2025127889A1

The present disclosure relates to a composition for inducing migration of activated B cells to a germinal center, the composition including a substance that induces CD11b expression in B cells, a production method therefor, or use thereof. In one aspect, the present disclosure relates to immunostimulation and maintenance or improvement of mucosal flora using the substance that induces the CD11b expression in B cells.

METHOD FOR PREPARING BIOFLOC CULTURE MEDIUM BY USING ORGANIC WASTES

Resumen de: WO2025081938A1

Provided is a method for preparing a biofloc culture medium by using organic wastes. The method comprises: adding a first auxiliary material to organic wastes, uniformly mixing same to obtain a mixture, and adjusting the water content of the mixture to 45-55%; inoculating an activated Bacillus subtilis seed culture, Bacillus licheniformis seed culture and Saccharomyces cerevisiae seed culture into the mixture according to a ratio, and performing fermentation with stirring and ventilation, so as to obtain a fermented product; adding a second auxiliary material to the fermented product, and uniformly mixing same to obtain the biofloc culture medium. In the finished biofloc product prepared by the method, the viable count of Bacillus subtilis is greater than or equal to 400 million cfu/g, the viable count of Bacillus licheniformis is greater than or equal to 200 million cfu/g, the viable count of Saccharomyces cerevisiae is greater than or equal to 1200 million cfu/g, the total number of bacterial colonies is greater than or equal to 8000 million cfu/g, and no salmonella is detected. The present application can solve the pollution problem of livestock and poultry manure and further achieves recycling utilization of livestock and poultry manure.

TUMOR NEOANTIGEN VACCINE SYSTEM SPECIFICALLY MARKING HETEROLOGOUS PROTEIN, AND USE THEREOF

Resumen de: WO2025081515A1

The present invention provides a tumor neoantigen vaccine system specifically marking a heterologous protein, and a use thereof. The vaccine system is composed of a heterologous protein mRNA vaccine and a recombinant oncolytic virus; the heterologous protein mRNA vaccine is used to induce an organism to generate heterologous protein-specific memory T cells, and the recombinant oncolytic virus is used to promote a tumor to express microorganism-derived tumor neoantigens. When pre-immunized memory T cells detect these marked specific neoantigens, the tumor expressing the neoantigens is quickly activated and killed, the release of tumor autoantigens is promoted, dendritic cells phagocytize antigens to further initiate an anti-tumor response, and a systemic anti-tumor immune effect is activated by means of antigenic epitope spreading.

標的微生物を検出するための反応媒体、及び関連する方法

Resumen de: AU2023262222A1

The invention relates to a gelled reaction medium for the detection, identification, enumeration and/or isolation of at least one target microorganism in a sample that may contain same, comprising at least one binding partner specific to a component of a target microorganism or of a component derived from said microorganism, coupled to at least one nanoparticle to form at least one binding conjugate.

鼠伤寒沙门菌毒力基因Ict的鉴定及其减毒疫苗候选株的制备与应用

Resumen de: CN119842745A

本发明公开了鼠伤寒沙门菌毒力基因Ict的鉴定及其减毒疫苗候选株的制备与应用。本发明选择强毒力鼠伤寒沙门菌SL1344株作为亲本株，将其中降解代谢衣康酸的关键毒力基因Ict进行敲除，构建鼠伤寒沙门菌SL1344减毒疫苗候选株。通过小鼠动物毒力实验、免疫保护力实验和安全性实验等证实该疫苗候选株SL1344‑ΔIct缺失株，不仅对动物的致病力显著降低，且提供了良好的免疫原性和免疫保护力。本发明实现对强毒力鼠伤寒沙门氏菌株的减毒，可广泛应用于沙门菌的防控，为研制沙门菌的减毒活疫苗及活载体疫苗奠定基础。

Duplex fluorescent PCR detection primer probe group for duck salmonella enteritidis and salmonella typhimurium, kit, and use thereof

Resumen de: GB2634693A

A duplex fluorescent PCR detection primer probe group of duck Salmonella enteritidis and Salmonella typhimurium, a kit, and the use thereof. Comparative analysis on the whole genomes of Salmonella enteritidis and Salmonella typhimurium is performed to screen out as identification targets a specific fragment Sdf I of lyg D gene of Salmonella enteritidis and a specific gene STM4497 of Salmonella typhimurium, and the present application designs specific primers and probes.

Rapid diagnosing Composition for detecting multiple Salmonella enterica serovars

Resumen de: KR20250049691A

본 발명은 살모넬라 혈청형 동시 검출을 위한 신속 진단 조성물에 관한 것으로서, 본 발명에서는 인간에서 발병률이 높은 여러 살모넬라 엔테리카(Salmonella enterica) 혈청형을 진단하기 위한 신속 도트-블롯 면역분석법을 개발하였다. 10개의 상업용 항체(4개의 다클론 항체 및 6개의 단클론 항체)에 대한 적용 가능성을 2016년 미국에서 67.5%의 살모넬라 감염 사례와 관련된 18개의 혈청형을 사용하여 시험하였다. Ab 3(다클론; 18개 혈청형 중 8개), Ab 8(단클론; 18개 혈청형 중 13개) 및 Ab 9(단클론; 18개 혈청형 중 10개) 항체는 웨스턴 블롯에서 높은 검출율을 나타냈고, 두 항체의 조합(Ab 3+8, Ab 3+9 및 Ab 8+9)을 도트-블롯 분석에 적용하였다. Ab 3+8의 조합은 시험된 18개의 혈청형 중 15개를 식별할 수 있었는데, 이는 S. Enteritidis, S. Typhimurium, S. Javiana, S. I 4,5,12:i:-, S. Infantis, S. Montevideo, S. Braenderup, S. Thompson, S. Saintpaul, S. Heidelberg, S. Oranienburg, S. Bareilly, S. Berta, S. Agona 및 S. Anatum을 포함하며, 2016년 미국에서 53.7%의 살모넬라 감염 사례와 관련되어 있다. 본 발명에서 최적화한 면역분석법은 3시간 안에 주요 15종의 혈청형을 진단할 수 있고, 이러한 비용 효율적이고 신속한 방법은 살모넬라 검출을 위한 현장 비색 방법으로 유용하게 활용될 수 있을 것으�

SipD重组蛋白在制备检测禽沙门氏菌抗体的间接ELISA检测试剂盒中的应用

Resumen de: CN119804862A

本发明涉及血清学检测技术领域，特别是涉及SipD重组蛋白在制备检测禽沙门氏菌抗体的间接ELISA检测试剂盒中的应用。本发明通过大量研究，成功筛选出用于检测禽沙门氏菌抗体的特异性抗原‑SipD蛋白。本发明以禽沙门氏菌III型分泌系统SipD亚基(SipD蛋白)为抗原，经蛋白表达纯化后获得包被抗原(SipD重组蛋白)，通过反应条件的摸索与优化，最终建立了灵敏性高、特异性强和重复性好的禽沙门氏菌间接ELISA检测方法。相比于传统的玻片凝集抗原检测方法，该方法极大地提高了检测通量和检测效率。该检测方法的建立对于人类、动物、食品中的沙门氏菌检测具有重要的公共卫生意义。

一种减毒沙门氏菌来源的细菌外膜囊泡蛋白载药系统及其制备方法和应用

Resumen de: CN119792228A

本发明公开了一种减毒沙门氏菌来源的细菌外膜囊泡蛋白载药系统及其制备方法和应用，本发明利用细菌外膜囊泡蛋白载药系统可以在细菌外膜囊泡表面实现蛋白药物的“即插即用”。本发明构建了细菌外膜囊泡蛋白载药系统。本发明敲除了减毒鼠伤寒沙门氏菌VNP20009的OmpA，并回补在胞外环结构域中插入SpyTag的重组OmpA，利用SpyTag/SpyCatcher间自发形成异肽键的性质，将SpyCatcher与蛋白药物的融合蛋白展示在细菌外膜囊泡表面，制备方法简单，容易操作，在细菌外膜囊泡表面展示多种蛋白，并高效保护和负载蛋白药物。结合细菌外膜囊泡的免疫刺激特性，实现肿瘤的高效治疗。

IMPROVED SALMONELLA VECTORED THERAPIES FOR TREATMENT OF CANCER

Nº publicación: EP4531880A2 09/04/2025

Solicitante:

UNIV FLORIDA [US]
University of Florida Research Foundation, Incorporated

Resumen de: WO2023235633A2

A genetically modified Salmonella cell (GMSC) engineered to exhibit specific targeting to cells and regulated delayed lysis in vivo, the GMSC comprising a first heterologous nucleic acid that encodes a first gene product that causes the GMSC to be selectively localized to and/or internalized by a target cell in vivo and a second heterologous nucleic acid that encodes a second gene product that facilitates killing of the target cells following internalization.